Treatment of vascular dementia - Evidence from clinical trials with cholinesterase inhibitors

Neurological Research

Volumn 26, Issue 5, 2004, Pages 603-605

  Erkinjuntti, Timo ^a   Román, Gustavo ^b,d   Gauthier, Serge ^c  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Cerebrovascular disease; Cholinesterase inhibitors; Dementia; Elderly; Vascular dementia

Indexed keywords

ANTICOAGULANT AGENT; CARDIOVASCULAR AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; PLACEBO; RIVASTIGMINE;

ALZHEIMER DISEASE; ANOREXIA; ARTHRALGIA; ARTICLE; BRADYCARDIA; BRAIN INJURY; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHOLINERGIC SYSTEM; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DEMENTIA; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FOREBRAIN; HEADACHE; HUMAN; LEG CRAMP; META ANALYSIS; MULTIINFARCT DEMENTIA; NAUSEA; PATHOGENESIS; SYNCOPE; SYSTEMATIC REVIEW;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; CEREBROVASCULAR DISORDERS; CHOLINERGIC FIBERS; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS; COGNITION; DEMENTIA, VASCULAR; HUMANS; NOOTROPIC AGENTS; TREATMENT OUTCOME;

EID: 3042750659     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/01610425017631     Document Type: Article

References (21)

1. Vinters HV, Ellis WG, Zarow C, et al. Neuropathologic substrates of ischemic vascular dementia. J Neuropathol Exp Neurol 2000; 60: 658-659
2. Selden NR, Gitelman DR, Salamon-Murayama N, et al. Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain 1998; 121: 2249-2257
3. Mesulam M, Siddique T, Cohen B. Cholinergic denervation in a pure multi-infarct state: Observations on CADASIL. Neurology 2003; 60: 1183-1185
4. Togashi H, Matsumoto K, Yoshida M. Neurochemical profiles in cerbrospinal fluid of stroke-prone spontaneously hypertensive rat. Neurosci Lett 1994; 166: 117-120
5. Freidle RL. A comparative histochemical mapping of the distribution of butrylcholinesterase in the brains of four species of animals, including man. Acta Anat (Basel) 1967; 66: 161-177
6. Court JA, Perry EK, Kalaria RN. Neurotransmitter control of the cerebralk vasculature and abnormalities in vascular dementia. In: Erkinjuntti T, Gauthier S, eds. Vascular cognitive impairment. London: Martin Duniz Ltd, 2002: pp. 167-185
7. Winblad B, Brodaty H, Gauthier S, et al. Pharmacotherapy of Alzheimer's disease: Is there a need to redefine treatment success? Int J Geriatr Psychiatry 2001; 16: 388-390
8. Pratt RD, Perdomo CA. The donepezil VaD 307 and 308 study groups. Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefits. Ann N Y Acad Sci 2002; 977: 513-522
9. Black S, Roman GC, Geldmacher DS, et al. Efficacy and tolerability of Donepezil in vascular dementia. Positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003; 34: 2323-2332
10. Wilkinson D, Doody R, Helme R, et al. Donepezil in vascular dementia. A randomized, placebo-controlled study. Neurology 2003; 61: 479-486
11. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: Diagnostic criteria for reserach studies. Report of the NINDS-AIREN International Work Group. Neurology 1993; 43: 250-260
12. Erkinjuntti T, Kurz A, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial. Lancet 2002; 359: 1283-1290
13. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34(7): 939-944
14. Erkinjuntti T, Kurz A, Small GW, et al. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. Clin Therapeut 2003; 25: 1765-1782
15. Small G, Erkinjuntti T, Kurz A, Lilienfeld S. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease. CNS Drugs 2003; 17: 905-914
16. Erkinjuntti T. Cognitive decline and treatment options for patients with vascular dementia. Acta Neurologica Scandinavica 2002; 106 (Supple. 178): 15-18
17. Kurz AF, Erkinjuntti T, Small GW, et al. Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease. Eur J Neurol 2003; 10: 663-640
18. Moretti R, Torre P, Antonello RM, Cazzato G. Rivastigmine in subcortical vascular dementia: A comparison trial on efficacy and tolerability for 12 months follow-up. Eur J Neurol 2001; 8: 361-362
19. Moretti R, Torre P, Antonello RM, et al. Rivastigmine in subcortical vascular dementia: An open 22-month study. J Neurol Sci 2002; 203: 141-146
20. Kumar V, Anand R, Messian J. An efficacy and safety analysis of Exelon in Alzheimer's disease with concurrent vascular risk factors. Eur J Neurol 2000; 7: 159-169
21. Erkinjuntti T, Skoog I, Lane R, Andrews C. Rivastigmine in patients with Alzheimer's disease and concurrent hypertension. Int J Clin Pract 2002; 56: 791-796